For the past 2 years, the ‘Advance of the Year’ has been immunotherapy. This innovative shift in the way in which cancer is treated has transformed care for many patients. In fact, ASCO estimates that immune checkpoint inhibitors could save 250,000 years of life for U.S. patients with advanced lung cancer for whom a checkpoint inhibitor could be prescribed. Immune checkpoint inhibitors are medicines that release the brakes on the body’s immune system, unleashing it to fight cancer.
The 2018 Advance of the Year is a new kind of immunotherapy known as chimeric antigen receptor (CAR) T-cell therapy.